
    
      The main purpose of this follow-up study is to detect events suggestive of delayed adverse
      effects of the study drug by review of clinical histories and discussion with subjects to
      identify/elicit significant medical events, including but not limited to hematologic,
      malignant, autoimmune, neurologic, and hepatic events.
    
  